BlackRock Investment Management’s Asterias Biotherapeutics Inc. Series A AST Stock Holding History

BlackRock Investment Management’s Portfolio AST Stock Details AST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$382K	Buy	82,955 +686	+0.8%	+$2.83K	﹤0.01%	3117
2016 Q3	$349K	Buy	82,269 +8,962	+12%	+$29K	﹤0.01%	3147
2016 Q2	$176K	Buy	73,307 +36,782	+101%	+$133K	﹤0.01%	3285
2016 Q1	$172K	Buy	36,525 +775	+2%	+$3K	﹤0.01%	3189
2015 Q4	$140K	Hold	35,750	–	–	﹤0.01%	3259
2015 Q3	$138K	Sell	35,750 -648	-2%	-$2.98K	﹤0.01%	3283
2015 Q2	$167K	Buy	+36,398	New	+$349K	﹤0.01%	3286

Other funds holding AST

Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return

NFC

Northeast Financial Consultants Westport, Connecticut $2.45B AUM 15.14% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return

Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock Investment Management's AST Position: Q4 2016 in Review

BlackRock Investment Management increased its Asterias Biotherapeutics Inc. Series A (AST) stake by 0.83% in Q4 2016, buying an estimated $2.83K and bringing the position to 82,955 shares worth $382K. The position accounts for ﹤0.01% of the portfolio, ranked #3117.

BlackRock Investment Management first reported a position in AST in Q2 2015 and has held it in 7 quarters since. 66 funds tracked by Wall St. Rank hold AST as of Q4 2016.

BlackRock Investment Management held 82,955 shares of Asterias Biotherapeutics Inc. Series A worth $382K as of Q4 2016.
BlackRock Investment Management bought 686 Asterias Biotherapeutics Inc. Series A shares in Q4 2016, an estimated $2.83K.
Asterias Biotherapeutics Inc. Series A made up ﹤0.01% of BlackRock Investment Management's portfolio in Q4 2016, its #3117 holding.
BlackRock Investment Management first reported a position in Asterias Biotherapeutics Inc. Series A in Q2 2015 and has held it in 7 quarters since.
66 funds tracked by Wall St. Rank held Asterias Biotherapeutics Inc. Series A as of Q4 2016.

Based on BlackRock Investment Management's 13F filing for Q4 2016, filed 10 Feb 2017.